Unlike other cancers requiring up to two years of immunotherapy, CSCC patients can achieve lasting responses after just a few months. This "less is more" approach is crucial for minimizing toxicity in the elderly, comorbid patient population, especially those with organ transplants.
To mitigate organ rejection risk in transplant patients with CSCC, oncologists should coordinate with transplant teams to switch from drugs like tacrolimus to an mTOR inhibitor. This proactive switch can prevent rejection and may even enhance the immunotherapy's effectiveness.
For transplant or autoimmune patients, a prophylactic, tapering steroid regimen (e.g., 40mg prednisone tapered to 10mg) around immunotherapy infusions can prevent organ rejection or disease flares. This "conditioning" allows for safer administration of life-saving immunotherapy in vulnerable populations.
When counseling transplant patients about immunotherapy for CSCC, clinicians can cite retrospective data indicating a roughly 33% chance of organ rejection and a 20% chance of complete organ loss. This provides a clear, quantitative framework for informed consent and shared decision-making.
Because CSCC tumors shed high levels of DNA, cell-free DNA (cfDNA) serves as an effective real-time biomarker. A rapid drop in cfDNA levels can confirm a deep response, providing quantitative evidence to confidently stop immunotherapy early, aligning with the "less is more" strategy.
A patient's willingness to accept immunotherapy risk depends on the transplanted organ. Kidney transplant patients may proceed, knowing dialysis is a viable backup. For heart, lung, or liver transplant patients, rejection is life-threatening, often leading them to choose hospice over treatment.